

OX2R agonists pursuing narcolepsy (all small molecules)

Drug	Company	ROA	Highest Phase of Development	Key Data / Milestones	Development Status
Overporexton		Oral, BID	Phase 3	Statistically significant improvement over placebo on all endpoints in dual Phase 3 studies (FirstLight, RadiantLight)	Active
ALKS 2680		Oral, QD	Phase 2/3	NT1 (Vibrance-1) Ph2 data in Q3'25; NT2 (Vibrance-2) Ph2 data in fall 2025; IH (Vibrance-3) Ph2 initiated in 2025; FIC potential	Active
Danavorexton (TAK-925)		SC	Phase 2	First selective OX2R agonist	Active
ORX750		Oral, QD	Phase 2	Ph2 CRYSTAL-1 ongoing; FIC potential	Active
TAK-360		Oral, QD	Phase 2	FDA Fast-Track; POC in 2026	Active
JZP441		Oral	Phase 1	Program paused in 2023 due to visual disturbances & CV effects; Ph1 in NT1 recruiting	Active
E2086		Oral	Phase 1	Completed Ph1b; update pending	Active
ORX142		Oral	Phase 1	Ph1 initiated in June 2025; high potency	Active
IDOR-1141-8472		Likely oral	Preclinical	N/A	Active
TPM-1116		Oral	Preclinical	N/A	Active
Patent-mined Asset		TBD	Preclinical	N/A	Active
Patent-mined Asset		TBD	Preclinical	N/A	Active
Patent-mined Asset		TBD	Preclinical	N/A	Active
Patent-mined Asset		TBD	Preclinical	N/A	Active
Firazorexton (TAK-944)		Oral	Phase 2	Discontinued due to hepatotoxic effects	Inactive
Unnamed		Intranasal	Preclinical	N/A	Inactive
RTOXA-43		IP injection	Preclinical	N/A	Inactive
YNT-185	University of Tsukuba	Oral	Preclinical	N/A	Inactive